600521 华海药业
午间休市 11-06 11:29:53
资讯
新帖
简况
华海药业（600521）11月5日主力资金净买入8117.77万元
证券之星 · 08:20
华海药业（600521）11月5日主力资金净买入8117.77万元
11月5日华海药业涨5.24%，兴全趋势LOF基金重仓该股
证券之星 · 11-05 16:35
11月5日华海药业涨5.24%，兴全趋势LOF基金重仓该股
华海药业涨5.24%，开源证券二个月前给出“买入”评级
证券之星 · 11-05 16:35
华海药业涨5.24%，开源证券二个月前给出“买入”评级
股市必读：华海药业新发布《浙江华海药业股份有限公司关于下属子公司获得药物临床试验许可的公告》
证券之星 · 11-04 03:08
股市必读：华海药业新发布《浙江华海药业股份有限公司关于下属子公司获得药物临床试验许可的公告》
百奥泰贝伐珠单抗生物类似药遭百济神州“退货”；华海药业HB0056注射液慢阻肺病适应证获批临床丨医药早参
每日经济新闻 · 11-03
百奥泰贝伐珠单抗生物类似药遭百济神州“退货”；华海药业HB0056注射液慢阻肺病适应证获批临床丨医药早参
华海药业（600521）披露“华海转债”到期兑付结果暨股份变动公告，11月02日股价上涨1.48%
证券之星 · 11-02
华海药业（600521）披露“华海转债”到期兑付结果暨股份变动公告，11月02日股价上涨1.48%
华海药业(600521.SH)：HB0056注射液项目新增适应症获得药物临床试验批准
智通财经 · 11-02
华海药业(600521.SH)：HB0056注射液项目新增适应症获得药物临床试验批准
华海药业（600521）2026年三季报简析：营收净利润同比双双增长
证券之星 · 10-31
华海药业（600521）2026年三季报简析：营收净利润同比双双增长
华海药业（600521）披露2026年前三季度计提资产减值准备公告，10月30日股价上涨2.26%
证券之星 · 10-30
华海药业（600521）披露2026年前三季度计提资产减值准备公告，10月30日股价上涨2.26%
华海药业(600521.SH)发布前三季度业绩，归母净利润10.6亿元，同比增长178.61%
智通财经 · 10-29
华海药业(600521.SH)发布前三季度业绩，归母净利润10.6亿元，同比增长178.61%
股市必读：华海药业新发布《浙江华海药业股份有限公司关于“华海转债”到期兑付暨摘牌的公告》
证券之星 · 10-26
股市必读：华海药业新发布《浙江华海药业股份有限公司关于“华海转债”到期兑付暨摘牌的公告》
华海药业（600521）披露“华海转债”到期兑付暨摘牌公告，10月22日股价下跌3.06%
证券之星 · 10-22
华海药业（600521）披露“华海转债”到期兑付暨摘牌公告，10月22日股价下跌3.06%
股市必读：华海药业新发布《浙江华海药业股份有限公司关于获得药品注册证书的公告》
证券之星 · 10-21
股市必读：华海药业新发布《浙江华海药业股份有限公司关于获得药品注册证书的公告》
华海药业(600521.SH)：腺苷钴胺胶囊获得药品注册证书
智通财经 · 10-19
华海药业(600521.SH)：腺苷钴胺胶囊获得药品注册证书
股市必读：华海药业新发布《浙江华海药业股份有限公司第九届董事会第十七次临时会议决议公告》
证券之星 · 10-16
股市必读：华海药业新发布《浙江华海药业股份有限公司第九届董事会第十七次临时会议决议公告》
华海药业最新公告：控股子公司华奥泰拟增资扩股引入不超3.5亿元外部投资人
证券之星 · 10-15
华海药业最新公告：控股子公司华奥泰拟增资扩股引入不超3.5亿元外部投资人
华海药业：华奥泰拟增资不超过3.5亿元
格隆汇 · 10-15
华海药业：华奥泰拟增资不超过3.5亿元
华海药业最新公告：拟向参股公司华海天衡增资约1.97亿元
证券之星 · 10-12
华海药业最新公告：拟向参股公司华海天衡增资约1.97亿元
华海药业：拟1.97亿元同比例增资参股公司华海天衡
格隆汇 · 10-12
华海药业：拟1.97亿元同比例增资参股公司华海天衡
股市必读：华海药业新发布《浙江华海药业股份有限公司可转换公司债券转股结果暨股份变动公告》
证券之星 · 10-12
股市必读：华海药业新发布《浙江华海药业股份有限公司可转换公司债券转股结果暨股份变动公告》
加载更多
公司概况
公司名称：
浙江华海药业股份有限公司
所属行业：
医药制造业
上市日期：
2003-03-04
主营业务：
浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是心血管类原料药、精神障碍类原料药、神经系统类原料药、抗感染类原料药、消化类治疗药、呼吸类治疗药、抗肿瘤类治疗药、内分泌类治疗药。
发行价格：
15.55
{"stockData":{"symbol":"600521","market":"SH","secType":"STK","nameCN":"华海药业","latestPrice":17.68,"timestamp":1793935793000,"preClose":17.87,"halted":0,"volume":17884718,"delay":0,"changeRate":-0.0106,"floatShares":1500000000,"shares":1500000000,"eps":0.6307,"marketStatus":"午间休市","change":-0.19,"latestTime":"11-06 11:29:53","open":17.44,"high":17.9,"low":17.43,"amount":317000000,"amplitude":0.0263,"askPrice":17.69,"askSize":127,"bidPrice":17.67,"bidSize":54,"shortable":0,"etf":0,"ttmEps":0.6307,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793941200000},"marketStatusCode":3,"adr":0,"adjPreClose":17.87,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":19.66,"lowLimit":16.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1499554552,"isCdr":false,"pbRate":2.73,"roa":"--","peRate":28.032345,"roe":"10.8%","epsLYR":0.18,"committee":-0.420571,"marketValue":26512000000,"turnoverRate":0.0119,"status":1,"floatMarketCap":26512000000},"requestUrl":"/m/hq/s/600521","defaultTab":"news","newsList":[{"id":"2681881799","title":"华海药业（600521）11月5日主力资金净买入8117.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681881799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681881799?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:20","pubTimestamp":1793924417,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月5日收盘，华海药业报收于17.87元，上涨5.24%，换手率3.55%，成交量53.22万手，成交额9.36亿元。近5日资金流向一览见下表：华海药业融资融券信息显示，融资方面，当日融资买入9665.5万元，融资偿还9092.59万元，融资净买入572.91万元。华海药业主营业务：多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600008376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600521","BK0012","BK0188","BK0185","BK0070","BK0028","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681041766","title":"11月5日华海药业涨5.24%，兴全趋势LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681041766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681041766?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:35","pubTimestamp":1793867725,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日华海药业涨5.24%，收盘报17.87元，换手率3.55%，成交量53.22万手，成交额9.36亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为兴证全球基金的兴全趋势LOF。兴全趋势LOF目前规模为116.03亿元，最新净值0.7581，较上一交易日上涨5.61%，近一年上涨9.77%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500029212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0185","BK0028","BK0201","163402","BK0012","600521","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681041474","title":"华海药业涨5.24%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2681041474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681041474?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:35","pubTimestamp":1793867710,"startTime":"0","endTime":"0","summary":"今日华海药业涨5.24%，收盘报17.87元。2026年8月28日，开源证券研究员余汝意,阮帅发布了对华海药业的研报《公司信息更新报告：2026上半年业绩稳健增长，创新药进展顺利》，该研报对华海药业给出“买入”评级。研报中预计公司2026-2028年归母净利润为9.30/7.65/9.49亿元，当前股价对应PE为26.8/32.6/26.2倍，考虑公司创新药领域的积极进展，维持“买入”评级。华海药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500029209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680779003","title":"股市必读：华海药业新发布《浙江华海药业股份有限公司关于下属子公司获得药物临床试验许可的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680779003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680779003?lang=zh_cn&edition=full","pubTime":"2026-11-04 03:08","pubTimestamp":1793732892,"startTime":"0","endTime":"0","summary":"公司公告汇总浙江华海药业股份有限公司关于下属子公司获得药物临床试验许可的公告上海华奥泰生物药业股份有限公司及华博生物医药技术（上海）有限公司收到国家药监局签发的HB0056注射液新增适应症《药物临床试验批准通知书》。浙江华海药业股份有限公司关于“华海转债”到期兑付结果暨股份变动的公告“华海转债”于2026年11月1日到期，兑付登记日为2026年10月30日，兑付资金发放日为2026年11月2日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400004454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600521","BK0201","BK0028","BK0070","BK0239","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680791112","title":"百奥泰贝伐珠单抗生物类似药遭百济神州“退货”；华海药业HB0056注射液慢阻肺病适应证获批临床丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2680791112","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680791112?lang=zh_cn&edition=full","pubTime":"2026-11-03 07:01","pubTimestamp":1793660501,"startTime":"0","endTime":"0","summary":"丨2026年11月3日星期二丨NO.1百奥泰贝伐珠单抗生物类似药遭百济神州“退货”11月2日，百奥泰公告称，基于对公司和百济神州双方均有利的战略考量，经双方协商一致，公司于2026年11月1日从百济神州重新获得BAT1706（贝伐珠单抗）相关知识产权及其在中国地区的全部产品权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033919222498.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033919222498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU2272731782.SGD","ONC","LU1770034418.SGD","LU2272731865.HKD","BK0185","BK1574","LU0588546209.SGD","LU2328871848.SGD","BK1500","BK0201","BK0012","XPH","BK4526","LU1719994722.HKD","LU2473716301.USD","BK1515","LU0228659784.USD","159938","BK1161","KURE","BK0070","BK1583","09939","LU2272731600.USD","BK0239","IE00B5TLWC47.USD","BK0188","BK4585","LU0828237510.HKD","LU2322448791.USD","PPH","LU1992135472.HKD","LU2322448957.HKD","LU1251922891.USD","LU1969619763.USD","688235","BK0028","LU0307460666.USD","BK1588","LU1303224171.USD","BK4139","600521","IBB","06160","LU1992135399.USD","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680763979","title":"华海药业（600521）披露“华海转债”到期兑付结果暨股份变动公告，11月02日股价上涨1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680763979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680763979?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:07","pubTimestamp":1793628427,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘，华海药业报收于16.5元，较前一交易日上涨1.48%，最新总市值为247.42亿元。近日，浙江华海药业股份有限公司发布《关于“华海转债”到期兑付结果暨股份变动的公告》。公告显示，“华海转债”已于2026年11月1日到期，兑付登记日为2026年10月30日，兑付资金发放日为2026年11月2日。本次到期兑付数量为18,043,910张，兑付本金1,804,391,000元，兑付总金额1,984,830,100元。截至2026年10月30日，累计有38,208,000元可转债转股，累计转股数量2,308,775股，未转股部分已完成兑付。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200036450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0201","BK0012","BK0239","BK0188","600521","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680734918","title":"华海药业(600521.SH)：HB0056注射液项目新增适应症获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680734918","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680734918?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:31","pubTimestamp":1793608266,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业 发布公告，近日，公司的下属子公司上海华奥泰生物药业股份有限公司及华博生物医药技术(上海)有限公司收到国家药品监督管理局核准签发的HB0056注射液项目新增适应症的《药物临床试验批准通知书》。HB0056通过同步阻断两条信号通路，有望在抑制气道炎症的同时干预组织重塑，为COPD提供差异化治疗策略。相比现有单靶点生物制剂，HB0056具有双通路干预的机制创新优势及潜在临床应用价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","600521","BMED","BK0185","BK0188","IBBJ","BK0201","BK0012","IBBQ","PSYK","MDTX","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679224423","title":"华海药业（600521）2026年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2679224423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679224423?lang=zh_cn&edition=full","pubTime":"2026-10-31 11:17","pubTimestamp":1793416655,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期华海药业发布2026年三季报。根据财报显示，华海药业营收净利润同比双双增长。截至本报告期末，公司营业总收入74.25亿元，同比上升15.86%，归母净利润10.6亿元，同比上升178.61%。持有华海药业最多的基金为兴全趋势LOF，目前规模为116.03亿元，最新净值0.7131，较上一交易日下跌2.86%，近一年下跌0.81%。本文数据来源于华海药业2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100023697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679216843","title":"华海药业（600521）披露2026年前三季度计提资产减值准备公告，10月30日股价上涨2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679216843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679216843?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:42","pubTimestamp":1793360572,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，华海药业报收于16.26元，较前一交易日上涨2.26%，最新总市值为243.82亿元。浙江华海药业股份有限公司于2026年10月29日召开第九届董事会第十八次临时会议，审议通过《关于公司2026年前三季度计提资产减值准备的议案》。本次计提减少公司2026年前三季度利润总额5,092.99万元，能够更加公允地反映公司资产状况和经营成果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000048740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0239","BK0185","BK0188","BK0201","BK0012","BK0028","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679284281","title":"华海药业(600521.SH)发布前三季度业绩，归母净利润10.6亿元，同比增长178.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679284281","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679284281?lang=zh_cn&edition=full","pubTime":"2026-10-29 23:27","pubTimestamp":1793287651,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)披露2026年第三季度报告，前三季度公司实现营业收入74.25亿元，同比增长15.86%;归母净利润10.6亿元，同比增长178.61%;扣非净利润7.02亿元，同比增长159.96%;基本每股收益0.71元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678369751","title":"股市必读：华海药业新发布《浙江华海药业股份有限公司关于“华海转债”到期兑付暨摘牌的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678369751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678369751?lang=zh_cn&edition=full","pubTime":"2026-10-26 02:40","pubTimestamp":1792953620,"startTime":"0","endTime":"0","summary":"股本股东变化业绩披露要点机构调研要点公司公告汇总浙江华海药业股份有限公司关于“华海转债”到期兑付暨摘牌的公告“华海转债”将于2026年11月1日到期，兑付登记日为2026年10月30日，兑付本息金额为110元/张（含税），兑付资金发放日为2026年11月2日。浙江华海药业股份有限公司详式权益变动报告书信息披露义务人陈保华将其持有的2813.00万元“华海转债”全部转换为公司A股普通股，转股价格16.50元/股，合计转股1,704,847股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0188","600521","BK0201","BK0012","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677834961","title":"华海药业（600521）披露“华海转债”到期兑付暨摘牌公告，10月22日股价下跌3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677834961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677834961?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:05","pubTimestamp":1792677920,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘，华海药业报收于16.13元，较前一交易日下跌3.06%，最新总市值为241.51亿元。近日，浙江华海药业股份有限公司发布《关于“华海转债”到期兑付暨摘牌的公告》。公告显示，公司发行的“华海转债”将于2026年11月1日到期，兑付登记日为2026年10月30日，兑付本息金额为110元/张（含税），兑付资金发放日为2026年11月2日。2026年10月27日为最后交易日，2026年10月28日起停止交易，2026年10月30日为最后转股日，2026年11月2日起摘牌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200041920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0185","BK0028","600521","BK0188","BK0070","BK0012","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677061825","title":"股市必读：华海药业新发布《浙江华海药业股份有限公司关于获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677061825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677061825?lang=zh_cn&edition=full","pubTime":"2026-10-21 01:39","pubTimestamp":1792517948,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月20日主力资金净流出833.27万元，占总成交额2.0%； 公司公告汇总：华海药业获腺苷钴胺胶囊《药品注册证书》，视同通过一致性评价，2026年上半年国内市场销售金额预计约2.24亿元。公司公告汇总浙江华海药业股份有限公司关于获得药品注册证书的公告浙江华海药业股份有限公司近日收到国家药品监督管理局核准签发的腺苷钴胺胶囊《药品注册证书》，药品批准文号为国药准字H20266225，注册分类为化学药品3类。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600521","BK0201","BK0070","BK0028","BK0239","BK0185","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676046405","title":"华海药业(600521.SH)：腺苷钴胺胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2676046405","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676046405?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:28","pubTimestamp":1792402106,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的腺苷钴胺胶囊的《药品注册证书》。腺苷钴胺胶囊适用于巨幼红细胞性贫血，营养不良性贫血、妊娠期贫血、多发性神经炎、神经根炎、三叉神经痛、坐骨神经痛、神经麻痹;也可用于营养性疾患以及放射线和药物引起的白细胞减少症的辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","600521","BK0028","BK0239","BK0070","BK0201","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675534354","title":"股市必读：华海药业新发布《浙江华海药业股份有限公司第九届董事会第十七次临时会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675534354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675534354?lang=zh_cn&edition=full","pubTime":"2026-10-16 01:47","pubTimestamp":1792086429,"startTime":"0","endTime":"0","summary":"公司公告汇总浙江华海药业股份有限公司第九届董事会第十七次临时会议决议公告浙江华海药业股份有限公司第九届董事会第十七次临时会议审议通过《关于控股子公司增资扩股并引入投资人的议案》。本次交易完成后，华海药业持有华奥泰股权比例不低于81.8643%，华奥泰仍纳入公司合并报表范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600002186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0201","BK0070","BK0239","BK0028","600521","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582831","title":"华海药业最新公告：控股子公司华奥泰拟增资扩股引入不超3.5亿元外部投资人","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582831","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582831?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:19","pubTimestamp":1792066759,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称，公司控股子公司上海华奥泰生物药业股份有限公司拟实施增资扩股并引入长三角基金等外部投资人，合计投资不超过3.5亿元，预计取得增资后股权比例不超过5.9829%。本次增资完成后，公司持有华奥泰股份比例不低于81.8643%，华奥泰仍为公司合并报表范围内子公司。本次交易定价以华奥泰投前估值55亿元为基础，每1元注册资本增资价格约10.9375元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500036626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600521","BK0185","BK0070","BK0028","BK0188","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675294584","title":"华海药业：华奥泰拟增资不超过3.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675294584","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675294584?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:17","pubTimestamp":1792066632,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0012","BK0185","BK0070","BK0188","BK0239","BK0028","600521","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674087488","title":"华海药业最新公告：拟向参股公司华海天衡增资约1.97亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674087488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674087488?lang=zh_cn&edition=full","pubTime":"2026-10-12 21:30","pubTimestamp":1791811800,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称，公司拟与王晶翼、云枢天衡共同向参股公司华海天衡增资合计5.97亿元，其中公司增资约1.97亿元。增资完成后，公司持有华海天衡的股份比例不变。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200034098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600521","BK0201","BK0070","BK0028","BK0239","BK0185","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674082388","title":"华海药业：拟1.97亿元同比例增资参股公司华海天衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2674082388","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674082388?lang=zh_cn&edition=full","pubTime":"2026-10-12 21:28","pubTimestamp":1791811724,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0012","BK0188","BK0201","BK0239","BK0028","BK0185","600521","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674884343","title":"股市必读：华海药业新发布《浙江华海药业股份有限公司可转换公司债券转股结果暨股份变动公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674884343","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674884343?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:00","pubTimestamp":1791738042,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，华海药业报收于17.45元，上涨4.8%，换手率4.82%，成交量72.2万手，成交额12.38亿元。公司公告汇总：截至2026年9月30日，“华海转债”累计转股7,927股，占转股前总股本的0.000545%，未转股余额为1,842,356,000元，占发行总额的99.9868%。公司公告汇总浙江华海药业股份有限公司可转换公司债券转股结果暨股份变动公告“华海转债”自2021年5月6日起进入转股期。转股价格由初始34.66元/股调整至16.50元/股，系因利润分配及转股价格下修所致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0239","BK0070","BK0012","600521","BK0188","BK0201"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793939121951,"stockEarnings":[{"period":"1week","weight":0.1239},{"period":"1month","weight":0.0936},{"period":"3month","weight":0.0182},{"period":"6month","weight":0.0939},{"period":"1year","weight":-0.0225},{"period":"ytd","weight":0.0604}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江华海药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"81072人(较上一季度减少2.64%)","perCapita":"18496股","listingDate":"2003-03-04","address":"浙江省台州市临海市汛桥镇汛大路88号","registeredCapital":"149955万元","survey":" 浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是心血管类原料药、精神障碍类原料药、神经系统类原料药、抗感染类原料药、消化类治疗药、呼吸类治疗药、抗肿瘤类治疗药、内分泌类治疗药。","listedPrice":15.55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华海药业,600521,华海药业股票,华海药业股票老虎,华海药业股票老虎国际,华海药业行情,华海药业股票行情,华海药业股价,华海药业股市,华海药业股票价格,华海药业股票交易,华海药业股票购买,华海药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}